Who are Amoxicillin during SRP's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CEPHALEXIN, Cefazolin + Gentamicin, Piperacillin/Tazobactam Intermittent infusion, Amoxicillin Short, Cefotaxime/ceftriaxone, Meropenem-Vaborbactam.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amoxicillin-during-srp.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Amoxicillin during SRP — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Amoxicillin during SRP (Amoxicillin during SRP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Penicillin antibiotic. Area: Infectious Disease.

phase 1 Penicillin antibiotic Penicillin-binding proteins Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Amoxicillin during SRP (Amoxicillin during SRP) — Belén Retamal-Valdes. Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Amoxicillin during SRP TARGET	Amoxicillin during SRP	Belén Retamal-Valdes	phase 1	Penicillin antibiotic	Penicillin-binding proteins
CEPHALEXIN	CEPHALEXIN		marketed	First-generation cephalosporin	Penicillin-binding proteins (PBPs)	1971-01-01
Cefazolin + Gentamicin	Cefazolin + Gentamicin	Mercy Health Ohio	marketed	Beta-lactam antibiotic + aminoglycoside antibiotic combination	Bacterial penicillin-binding proteins (cefazolin); bacterial 30S ribosomal subunit (gentamicin)
Piperacillin/Tazobactam Intermittent infusion	Piperacillin/Tazobactam Intermittent infusion	Ain Shams University	marketed	Beta-lactam/beta-lactamase inhibitor combination	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
Amoxicillin Short	Amoxicillin Short	Universita degli Studi di Genova	marketed	Beta-lactam antibiotic (aminopenicillin)	Penicillin-binding proteins (PBPs)
Cefotaxime/ceftriaxone	Cefotaxime/ceftriaxone	Centre Hospitalier Universitaire de Besancon	marketed	Third-generation cephalosporin	Penicillin-binding proteins (PBPs)
Meropenem-Vaborbactam	Meropenem-Vaborbactam	Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)	marketed	Carbapenem with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); serine beta-lactamases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Penicillin antibiotic class)

Belén Retamal-Valdes · 1 drug in this class
Centre Hospitalier Universitaire de Nice · 1 drug in this class
Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Amoxicillin during SRP — Competitive Intelligence Brief. https://druglandscape.com/ci/amoxicillin-during-srp. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing